Université Côte d'Azur, INSERM, CNRS, Institute of Molecular and Cellular Pharmacology, Laboratory of excellence DistALZ, 06560, Sophia-Antipolis, Valbonne, France.
Instituto de Ciências Biomédicas Department of Pharmacology, Universidade de São Paulo, São Paulo, Brazil.
Cell Death Dis. 2024 May 28;15(5):367. doi: 10.1038/s41419-024-06742-2.
Mitochondria dysfunctions and mitophagy failure have been associated with several Alzheimer's disease (AD) related molecular actors including amyloid beta (Aβ) and recently the amyloid precursor protein-C terminal fragments (APP-CTFs). The efficacy of the mitophagy process in neurons relies on regulated mitochondrial transport along axons involving a complex molecular machinery. The contribution of the amyloid precursor protein (APP) and its derived fragments to the mitochondrial transport machinery alterations in AD have not been investigated before. We report herein a change of the expression of mitochondrial transport proteins (SNPH and Miro1), motor adapters (TRANK1 and TRAK2), and components of the dynein and kinesin motors (i.e., IC1,2 and Kif5 (A, B, C) isoforms) by endogenous APP and by overexpression of APP carrying the familial Swedish mutation (APPswe). We show that APP-CTFs and Aβ concomitantly regulate the expression of a set of transport proteins as demonstrated in APPswe cells treated with β- and γ-secretase inhibitors and in cells Knock-down for presenilin 1 and 2. We further report the impact of APP-CTFs on the expression of transport proteins in AAV-injected C99 mice brains. Our data also indicate that both Aβ oligomers (Aβo) and APP-CTFs impair the colocalization of mitochondria and transport proteins. This has been demonstrated in differentiated SH-SY5Y naive cells treated with Aβo and in differentiated SH-SY5Y and murine primary neurons expressing APPswe and treated with the γ-secretase inhibitor. Importantly, we uncover that the expression of a set of transport proteins is modulated in a disease-dependent manner in 3xTgAD mice and in human sporadic AD brains. This study highlights molecular mechanisms underlying mitochondrial transport defects in AD that likely contribute to mitophagy failure and disease progression.
线粒体功能障碍和自噬体失败与几种阿尔茨海默病(AD)相关的分子因素有关,包括淀粉样β(Aβ)和最近的淀粉样前体蛋白 C 端片段(APP-CTFs)。神经元中自噬体的功效依赖于沿着轴突进行调节的线粒体运输,涉及到复杂的分子机制。淀粉样前体蛋白(APP)及其衍生片段对 AD 中线粒体运输机制改变的贡献以前尚未被研究过。我们在此报告线粒体运输蛋白(SNPH 和 Miro1)、运动适配器(TRANK1 和 TRAK2)以及动力蛋白和驱动蛋白的组成部分(即 IC1、2 和 Kif5(A、B、C)同工型)的表达变化由内源性 APP 和携带家族性瑞典突变的 APP(APPswe)引起。我们表明 APP-CTFs 和 Aβ 同时调节一组运输蛋白的表达,如在 APPswe 细胞用β-和γ-分泌酶抑制剂处理以及在敲低早老素 1 和 2 的细胞中所证明的。我们进一步报告了 APP-CTFs 对 AAV 注射 C99 小鼠大脑中运输蛋白表达的影响。我们的数据还表明,Aβ 寡聚体(Aβo)和 APP-CTFs 均会损害线粒体和运输蛋白的共定位。这在用 Aβo 处理的分化的 SH-SY5Y 原始细胞和表达 APPswe 并用 γ-分泌酶抑制剂处理的分化的 SH-SY5Y 和鼠原代神经元中得到了证明。重要的是,我们发现一组运输蛋白的表达在 3xTgAD 小鼠和人类散发性 AD 脑中以疾病依赖的方式被调节。这项研究强调了 AD 中线粒体运输缺陷的分子机制,这些机制可能导致自噬体失败和疾病进展。